IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Chen W. Liaw and I-Lin Lin Confirmation No.: 5835

Serial No.: 10/782,596 Art Unit No.: 1646

Filing Date: February 19, 2004 Examiner: Ruixiang Li

For: NUCLEIC ACID ENCODING HUMAN G PROTEIN-COUPLED RECEPTOR

Customer No.: 35133

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

VIA EXPRESS MAIL LABEL NO: EV770 975 312US

DATE SENT: February 22, 2006

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

	within three months of the filing date of the patent application.
	within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
\boxtimes	before the mailing date of a first Office Action on the merits.
	before the mailing date of a first Office Action on the merits or with the filing of a Request for Continued Examination under § 1 114

DOCKET NO: AREN11.US12.CON - 2 - PATENT SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT DATED FEB. 22, 2006

	date o	he mailing date of a first Office Action on the merits, but before the mailing f a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance 37 C.F.R. § 1.311, and accordingly is accompanied by:		
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below); or		
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or		
		No fee is owed by the applicant(s).		
	In accordance with 37 C.F.R. § 1.129(a), this Supplemental Information Disclosure Statement is being filed in connection with the \square first or \square secont After Final Submission, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.			
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. §1.17(p).			
\boxtimes	Copies of references (except the U.S. Patent documents) listed on the attached PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, are enclosed.			
	EXCE	CPT THAT:		
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.		
		In accordance with 37 C.F.R. § 1.98(d), copies of the references A35 and A37 on the attached PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application no. 09/417,044 for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.		
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.		
Stater	nent un	der 37 C.F.R. § 1.97(e)		
	the Su from a	ndersigned attorney hereby states that each item information contained in pplemental Information Disclosure Statement was cited in a communication of foreign patent office in a counterpart foreign patent application not more bree months prior to the filing of the Supplemental Information Disclosure tent.		

DOCKET NO: AREN11.US12.CON - 3 - PATENT SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT DATED FEB. 22, 2006

Staten	nent under 37 C.F.R. § 1.704(d)
	The undersigned attorney hereby states that each item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Supplemental Information Disclosure Statement.
Fees	
\boxtimes	No Fee is owed by the applicant(s).
	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.
Metho	d of Payment of Fees
	Attached is a check in the amount of \$ This form is submitted in duplicate.
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.
\boxtimes	No fee or Statement is required under 37 C.F.R. § 1.97(b) as no first Office Action on the merits has been received by Applicants.
	Respectfully submitted,

COZEN O'CONNOR

Michael A. Patané

Registration No. 42,982

Date: Feb. 22, 2006

COZEN O'CONNOR 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 Tel:215-665-6966

Fax: 215-701-2080

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

stitute for form 1449A/PTO

SPERMAN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/782,596			
Filing Date	February 19, 2004			
First Named Inventor	Chen Liaw			
Art Unit	1646			
Examiner Name	Ruixiang Li			
Attorney Docket Number	AREN11.US12.CON			

	U.S. PATENT DOCUMENTS						
Eveniese	Cite	Document Number	Publication/Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant		
Examiner Initials *	No.1	Number - Kind Code ² (if known)			Passages or Relevant Figures Appear		
	A30	US-5,462,856	10-31-1995	Lerner et al.			
	A31	US-6,051,386	04-18-2000	Lerner et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-		_			
		US-					
		US-					
		US-			· -		
_	1	US-					
		US-					
		US-					
	1	US-					

	FOREIGN PATENT DOCUMENTS						
F	Cito	Foreign Patent Document	Publication Date/Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)					
	!						
	 						

Examiner Signature	Date Considered	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

ct of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1446 Complete if Known Application Number 10/782,596 INFORMATION DISCLOSURE February 19, 2004 Filing Date STATEMENT BY APPLICANT First Named Inventor Chen Liaw Art Unit 1646 (Use as many sheets as necessary) Examiner Name Ruixiang Li 2 Attomey Docket Number AREN11.US12.CON Sheet of

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1					
	A32	Gracheck et al., Annual Rep. Med. Chem. (1993) 28:161-166.				
	A33	Major et al. "Challenges of high throughput screening against cell surface receptors," J. of Receptor and Signal Transduction Res. (1995) 15:595-607.				
· · ·	A34	Jayawickreme et al. "Gene expression systems in the development of high-throughput screens," Current Opinion in Biotechnology (1997) 629-634.				
	A35	Ji et al., "G Protein-Coupled Receptors," J. Biol. Chem. (1998) 273:17299-17302.	=			
	A36	Smith et al., Assays of Cycle Nucleotides: A Review of Current Techniques, App. Biochem Biotechnol (1993) 41:189-218.				
	A37	Murdoch et al., "Chemokine receptors and their role in inflammation and infectious diseases," <i>Blood</i> (2000) 95:3032-3043.				
		,				

<u></u>		
Examiner	Date	
	Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents P.O. Box 1450, Alexandria FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.